TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06648655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP-301
Description: Daily (QD) x 14 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily (QD) x 14 weeks.
Study: NCT04601428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IA therapy of HCC with CSR02-Fab-TF
Description: Intra-Arterial Infusion of CSR02-Fab-TF
Study: NCT06372522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitocin Injectable Product
Description: The primary dose of oxytocin is 1.0 mU/min, with an incremental increase by 2.5 mU/min every 30 minutes, until 20.0 mU/min, tittered to a target of 3-5 contractions in a 10-minute period, or active labor (dilatation \> 6 cm).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitocin Injectable Product
Description: The primary dose of oxytocin is 1.0 mU/min, with an incremental increase by 2.5 mU/min every 30 minutes, until 20.0 mU/min, tittered to a target of 3-5 contractions in a 10-minute period, or active labor (dilatation \> 6 cm).
Study: NCT04281225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention to Variability (ATV)
Description: In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and behavior that occur throughout the day, and to notice changes they experience with their hearing loss symptoms; noticing if it is better or worse and to ask why it may be.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention to Variability (ATV)
Description: In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and behavior that occur throughout the day, and to notice changes they experience with their hearing loss symptoms; noticing if it is better or worse and to ask why it may be.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants are told that the device they will be testing will improve their hearing, when in fact the device is not a hearing aid but just a metallic earring.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are told that the device they will be testing will improve their hearing, when in fact the device is not a hearing aid but just a metallic earring.
Study: NCT06315283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-44749
Description: Administered subcutaneously (sc)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral olanzapine
Description: Administered orally
Study: NCT05381441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Action Feedback and Engagement (SAFE) Loop
Description: Nursing units randomized to the intervention arm will undergo the SAFE Loop intervention, which involves five Key Attributes: (1) obtaining input from nurses on which problems to address; (2) focusing on selected high-priority events, (3) prompting nurses to report the high-priority events for a designated period and write more informative reports; (4) following standardized investigative procedures to integrate information from sources internal and external to CSMC, and (5) providing feedback to nurses about safety problems and mitigation plans. During all phases, the SAFE Loop Team collaborates with frontline nurses and Unit Managers.
Study: NCT06137378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: 200 mg KEYTRUDA® i. v. in 3-week cycle (q3w)
Study: NCT04864626

Intervention type: OTHER
Intervention: semi-standardized interview
Description: annual collection of the number of consultations and hospitalizations at the center, as well as the number of treatments

Intervention type: OTHER
Intervention: care experience questionary
Description: questionary with 12 questions to rate the quality of the telephone reception and your feelings during the interview
Study: NCT04301076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tissue and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT or CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT06385392

Intervention type: DEVICE
Intervention: Haptic module and insole device
Description: System for use in daily in-community use that detects the occurrence of freezing of gait (FOG) and triggers external cueing stimuli to unfreeze the individual.
Study: NCT06092216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: 900 mg of spesolimab intravenously (IV) administered every 4 weeks at Visits 2, 3, 4, 5, 6, 7, 8, 9.~If at visit 4 dosing schedule changes to every 3 weeks, Spesolimab will be administered at Visits 2, 3, 4, 5, 6, 8, 9, 10 and 11.
Study: NCT05437562

Intervention type: OTHER
Group type: OTHER
Intervention: Ewing Amputation
Description: All patients will receive Ewing Amputation to test feasibility.
Study: NCT06567730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ni-ti Closed-coil Spring
Description: Ni-Ti closed-coil spring is a passive compressed spring made up of super elastic Nickel-titanium. Two eyelets are attached to each side of the coil to facilitate its application. The eyelets will be engaged in the hooks of the second premolar and canine brackets and will apply a force of 150 gm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elastomeric Power chain
Description: Elastomeric power chains are resilient and latex-free orthodontic materials. They are made up of elastic material and consist of many connected rings. Each ring is engaged in a bracket to apply a force of 175-300 gm.
Study: NCT06252038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zoom Group Video (GV)
Description: Zoom delivery of the DPP. Participants have access to Prevent T2 Curriculum and connected technology to track weight and physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Directed (SD)
Description: Self directed delivery of the DPP. Participants have access to online curriculum, lifestyle coach and connected technology to track weight and physical activity.
Study: NCT05383274

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Optilume Urethral DCB
Description: The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
Study: NCT06559891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIVUS™ Renal Denervation System
Description: Renal artery catheterization procedure used to denervate the renal sympathetic nerves in the perivascular space using ultrasound energy.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: For those subjects randomized to the sham control, the angiogram will serve as the sham procedure.
Study: NCT06655714

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06654050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alrizomadlin
Description: Alrizomadlin (APG-115) oral tablets (150 mg) taken every other day on Days 1, 3, 5, 7, 9, 11, and 13 of every cycle (1 cycle=21 days) for 8 cycles (i.e., Course 1). Individuals with stable or responding disease may receive an additional 8 cycles (i.e., Course 2). Maximum (total) of 2 treatment courses.
Study: NCT06654245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone based interview
Description: Receive SHAREDCare navigator calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey using a questionnaire.
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic health record review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral
Description: Receive standard of care automated referrals
Study: NCT06655727

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound evaluation
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound evaluation
Description: No intervention
Study: NCT06041217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subcutaneous injections of semaglutide once-weekly at escalating doses every fourth week until maintenance dose of 2.4 mg of semaglutide is reached.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.
Study: NCT06272383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg dexamethasone
Description: 25% less than the standard practice of dexamethasone at 0.6mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.15 mg/kg dexamethasone
Description: 25% less than the standard practice of dexamethasone at 0.6mg/kg
Study: NCT06598423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Specialized soft contact lens 1
Description: These are daily-wear, daily-replacement lenses. They are identical to specialized soft contact lens 2 in material, comfort, and lens geometry. They differ only in their spectral profile.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Specialized soft contact lens 2
Description: These are daily-wear, daily-replacement lenses. They are identical to specialized soft contact lens 1 in material, comfort, and lens geometry. They differ only in their spectral profile.
Study: NCT06588686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buloxibutid
Description: Buloxibutid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buloxibutid
Description: Buloxibutid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06591819

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost
Description: Brachytherapy boost will be delivered and then whole pelvis proton radiation therapy in 5 fractions.
Study: NCT06590441

Intervention type: DEVICE
Intervention: Myopia control spectacles
Description: Myopia control spectacles fitted with temperature sensors
Study: NCT06587243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Animation Video
Description: The informational animation video will also take several minutes and will cover HPV disease, address specific concerns when identified, and the importance and safety of HPV vaccines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Animation Video
Description: The informational animation video will also take several minutes and will cover HPV disease, address specific concerns when identified, and the importance and safety of HPV vaccines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Animation Video
Description: The informational animation video will also take several minutes and will cover HPV disease, address specific concerns when identified, and the importance and safety of HPV vaccines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Narrative Video
Description: Personal narrative videos will consist of someone describing the person's own personal experience with HPV. The investigators have a collection of videos of personal narratives from different people that the investigators have cut to approximate several minutes in length so the investigators can tailor the personal narratives to match each study participant's race/ethnicity and gender as closely as possible.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Narrative Video
Description: Personal narrative videos will consist of someone describing the person's own personal experience with HPV. The investigators have a collection of videos of personal narratives from different people that the investigators have cut to approximate several minutes in length so the investigators can tailor the personal narratives to match each study participant's race/ethnicity and gender as closely as possible.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Narrative Video
Description: Personal narrative videos will consist of someone describing the person's own personal experience with HPV. The investigators have a collection of videos of personal narratives from different people that the investigators have cut to approximate several minutes in length so the investigators can tailor the personal narratives to match each study participant's race/ethnicity and gender as closely as possible.
Study: NCT06586827

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VCU-RRTC Online Course
Description: Approved by ACRE as its accrediting body and has been offered virtually through the VCU RRTC for over 15 years. The course currently entails:~i. Six modules ii. Six online discussion boards iii. Assignments in each module iv. One quiz per module v. Final assignment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VCU-RRTC Online Course
Description: Approved by ACRE as its accrediting body and has been offered virtually through the VCU RRTC for over 15 years. The course currently entails:~i. Six modules ii. Six online discussion boards iii. Assignments in each module iv. One quiz per module v. Final assignment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zoom Technical Assistance Sessions (6 total)
Description: Technical Assistance sessions will be provided to small groups of participants of 5-7 via Zoom technology. There will be one virtual TA session for each of the six modules that will last for 1 hour. The TA sessions will be provided by a trained SE expert/ mentor. The TA sessions will have instructional plans so that they are delivered consistently and will align with the associated module's content and will entail application and discussion that facilitates implementation and reflection of the material.
Study: NCT06602453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-8264
Description: GDC-8264 will be administered as per pre-defined regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-8264
Description: GDC-8264 will be administered as per pre-defined regimen.
Study: NCT05179668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered orally once daily
Study: NCT06535230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Manual anesthesia induction
Description: In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia induction with Target controlled infusions (TCI)
Description: Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic monitoring with pressure recording analytical method (PRAM)
Description: The pulse contour device MostCare (Vytech, Vygon, Padova, Italy) provides functional hemodynamic monitoring using the pressure recording analytical method.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic monitoring with pressure recording analytical method (PRAM)
Description: The pulse contour device MostCare (Vytech, Vygon, Padova, Italy) provides functional hemodynamic monitoring using the pressure recording analytical method.
Study: NCT05145764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Encapsulated suvorexant (matched for color, weight, and size)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated placebo (matched for color, weight, and size)
Study: NCT05707078

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Neck dissection
Description: Based on PET/CT scan patients will undergo neck dissection.
Study: NCT06076252

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Blumgart Anastomosis in LPD
Description: This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
Study: NCT06602453

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per pre-defined regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per pre-defined regimen.
Study: NCT04672044

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS and exercise
Description: active
Study: NCT06076252

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional Blumgart anastomosis in LPD
Description: This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
Study: NCT06154889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: consultations with a psychologist
Description: Consultations with a sports psychologist to decrease kinesiophobia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional reeducation
Description: Conventional reeducation
Study: NCT05470179

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid hyrax distalizer
Description: class 2 Angle malocclusion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid hyrax distalizer
Description: class 2 Angle malocclusion
Study: NCT04672044

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS+Exercise
Description: sham
Study: NCT06302933

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Blood samples collected from children followed in the Pediacam III ANRS12225 cohort
Study: NCT06656338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher HEI-2020 diet followed by lower HEI-2020 diet
Description: Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower HEI-2020 diet followed by higher HEI-2020 diet
Description: Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.
Study: NCT06655896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rapcabtagene autoleucel
Description: single infusion of rapcabtagene autoleucel

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: rituximab intravenous infusion (i.v.) as per protocol
Study: NCT06002100

Intervention type: OTHER
Intervention: fNIRS measurement
Description: Kernel Flow2 measurements.

Intervention type: OTHER
Intervention: fNIRS measurement
Description: Kernel Flow2 measurements.

Intervention type: OTHER
Intervention: fNIRS measurement
Description: Kernel Flow2 measurements.

Intervention type: OTHER
Intervention: fNIRS measurement
Description: Kernel Flow2 measurements.
Study: NCT06652568

Intervention type: DEVICE
Group type: OTHER
Intervention: ThinkSono System
Description: The ThinkSono Guidance System is a guidance software expected to help non-radiology specialist healthcare professionals produce compression ultrasound image data that meet or exceed the minimal image quality criteria for a remote diagnosis by an expert (e.g. radiologist).
Study: NCT05625087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib 300 mg once daily + fulvestrant 500 mg every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribociclib
Description: Ribocilcib 600 mg once daily 3 weeks on/1 week off + fulvestrant 500 mg every 28 days
Study: NCT06606119

Intervention type: OTHER
Intervention: Data and tissue collection
Description: Collection of bone marrow, blood, feces, medical record data, and patient response surveys.

Intervention type: OTHER
Intervention: Data and tissue collection
Description: Collection of bone marrow, blood, feces, medical record data, and patient response surveys.
Study: NCT06472622

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermal Pain Stimulation
Description: Thermal pain will be administered during fMRI neuroimaging via a thermal stimulation device (Medoc Ltd., Advanced Medical System, Israel; 510K: K052357; K041908; K922052) to examine brain activity corresponding to the experience of this stimulus. This device and associated system carries an FDA 510 (K) clearance.

Intervention type: DEVICE
Group type: OTHER
Intervention: Physical Effort Stimulation
Description: Physical effort will be administered during fMRI neuroimaging via a hand dynamometer attachment for a physiological monitoring system (BIOPAC Systems, Inc., Goleta, CA, USA) to examine brain activity corresponding to the experience of this stimulus. This device has not received pre-marked approval or 510 (K) clearance by the FDA.
Study: NCT06604494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: early feeding resumption
Description: Resumption of food on the 3rd or 4th day post-operatively with a mixed diet.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: late feeding resumption
Description: Resumption of food on the 7th day post-operatively with a mixed diet.
Study: NCT06599697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenously administered pooled human immunoglobulin (IVIG)
Description: IVIG 2g/kg every 4 weeks for 12 weeks (3 doses)